TP53 and prostate cancer: They also demonstrated that ectopic expression of miR-34a in p53-null or p53-mutated prostate cancer cells restores chemosensitivity to camptothecin by suppression of SIRT1 and consequent induction of cell cycle arrest and apoptosis.